1220 related articles for article (PubMed ID: 21451212)
1. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
[TBL] [Abstract][Full Text] [Related]
2. Esophagoprotective activity of angiotensin-(1-7) in experimental model of acute reflux esophagitis. Evidence for the role of nitric oxide, sensory nerves, hypoxia-inducible factor-1alpha and proinflammatory cytokines.
Pawlik MW; Kwiecien S; Pajdo R; Ptak-Belowska A; Brzozowski B; Krzysiek-Maczka G; Strzalka M; Konturek SJ; Brzozowski T
J Physiol Pharmacol; 2014 Dec; 65(6):809-22. PubMed ID: 25554985
[TBL] [Abstract][Full Text] [Related]
3. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor.
Brzozowska I; Targosz A; Sliwowski Z; Kwiecien S; Drozdowicz D; Pajdo R; Konturek PC; Brzozowski T; Pawlik M; Konturek SJ; Pawlik WW; Hahn EG
J Physiol Pharmacol; 2004 Dec; 55(4):773-90. PubMed ID: 15613743
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines.
Zwolinska-Wcislo M; Krzysiek-Maczka G; Ptak-Belowska A; Karczewska E; Pajdo R; Sliwowski Z; Urbanczyk K; Drozdowicz D; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Jun; 62(3):357-68. PubMed ID: 21893697
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection.
Fiorucci S; Di Lorenzo A; Renga B; Farneti S; Morelli A; Cirino G
J Pharmacol Exp Ther; 2004 Dec; 311(3):1264-71. PubMed ID: 15297470
[TBL] [Abstract][Full Text] [Related]
6. Esophagoprotection mediated by exogenous and endogenous melatonin in an experimental model of reflux esophagitis.
Konturek PC; Brzozowska I; Targosz A; Pawlik M; Kania J; Hess T; Kwiecien S; Konturek SJ; Reiter RJ; Brzozowski T
J Pineal Res; 2013 Aug; 55(1):46-57. PubMed ID: 23480366
[TBL] [Abstract][Full Text] [Related]
7. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
8. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves.
Konturek SJ; Zayachkivska O; Havryluk XO; Brzozowski T; Sliwowski Z; Pawlik M; Konturek PC; Cześnikiewicz-Guzik M; Gzhegotsky MR; Pawlik WW
J Physiol Pharmacol; 2007 Jun; 58(2):361-77. PubMed ID: 17622703
[TBL] [Abstract][Full Text] [Related]
9. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
11. Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin.
Brzozowski T; Konturek P; Konturek SJ; Kwiecień S; Sliwowski Z; Pajdo R; Duda A; Ptak A; Hahn EG
Int J Colorectal Dis; 2003 Jul; 18(4):320-9. PubMed ID: 12774247
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide-releasing aspirin but not conventional aspirin improves healing of experimental colitis.
Zwolinska-Wcislo M; Brzozowski T; Ptak-Belowska A; Targosz A; Urbanczyk K; Kwiecien S; Sliwowski Z
World J Gastroenterol; 2011 Sep; 17(36):4076-89. PubMed ID: 22039321
[TBL] [Abstract][Full Text] [Related]
13. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-releasing aspirin protects gastric mucosa against ethanol damage in rats with functional ablation of sensory nerves.
Konturek PC; Brzozowski T; Kania J; Konturek SJ; Hahn EG
Inflamm Res; 2003 Sep; 52(9):359-65. PubMed ID: 14504662
[TBL] [Abstract][Full Text] [Related]
15. Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion.
Yamato M; Nagahama K; Kotani T; Kato S; Takeuchi K
Digestion; 2005; 72(2-3):109-18. PubMed ID: 16172547
[TBL] [Abstract][Full Text] [Related]
16. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
17. Comparison of nitric oxide-releasing NSAID and vitamin C with classic NSAID in healing of chronic gastric ulcers; involvement of reactive oxygen species.
Brzozowski T; Kwiecień S; Konturek PC; Konturek SJ; Mitis-Musiol M; Duda A; Bielański W; Hahn EG
Med Sci Monit; 2001; 7(4):592-9. PubMed ID: 11433182
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of endogenous nitric oxide activity impairs the colonic sparing effect of rofecoxib, the cyclooxygenase-2 inhibitor and resveratrol, the preferential cyclooxygenase-1 inhibitor in the course of experimental colitis. Role of oxidative stress biomarkers and proinflammatory cytokines.
Kwiecień S; Wojcik-Grzybek D; Sliwowski Z; Targosz A; Chmura A; Magierowska K; Strzalka M; Glowacka U; Ptak-Belowska A; Magierowski M; Brzozowski T
J Physiol Pharmacol; 2023 Oct; 74(5):. PubMed ID: 38085520
[TBL] [Abstract][Full Text] [Related]
20. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Knight S; Johns EJ
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
